Intranasal Insulin for Weight Management During Smoking Cessation

Phase 2CompletedNCT02028871

Ajna Hamidovic26 enrolled

Overview

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Tobacco Abstinence Syndrome

Interventions

Intranasal InsulinDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * smokers (\>10 cig/day) for the past 1 year * normosmic olfactory function Exclusion Criteria: * previous/current use of insulin * current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder * current pregnancy (or lactation) * lifetime history of endocrine disease * excessive alcohol use (\>25 standard units of alcohol/week) * current use of illicit drugs * current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic agent * local infections, inflammation, structural abnormalities, or other nasal pathology * current use of any medications administered intranasally, including intranasal steroids

Locations (2)

UNM College of Pharmacy

Albuquerque, New Mexico, United States

UNM College of Pharmacy

Albuquerque, New Mexico, United States

Outcomes

Primary Outcomes

Amount Eaten in Taste Test

Time frame: 90 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.